Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Illumina lifts 2026 guidance on strong Q2; NovaSeq X demand supports upside

Jul 30, 2026, 4:12 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Issuer surprised to the upside with raised 2026 targets and strong NovaSeq X demand, which historically supports multiple-quarter upside in Illumina shares. Positive guidance beats typically translate into short- to medium-term price appreciation as investors re-rate the growth and margin trajectory.

AI summary

What happened, with direct paths to the underlying reporting

Illumina reported Q2 2026 revenue of about $1.159B, up 9.5% year over year, with ROW organic growth above 5%. The company raised FY2026 guidance to $4.60-$4.64B and non-GAAP EPS of $5.30-$5.40, driven by high NovaSeq X demand and expanded multiomics. Cash flow improved, reinforcing balance sheet strength despite China/ROW regulatory risk, supporting optionalities like buybacks or strategic investments.

Q2 revenue $1.159B, up 9.5% YoY; ROW organic growth >5%.
FY2026 guidance raised: revenue $4.60-4.64B, non-GAAP EPS $5.30-5.40.
NovaSeq X demand remains strong; GAAP margin 21.1%, non-GAAP 22.5%.
Cash flow improved: OCF $201M, free cash flow $162M; cash ~$1.17B.
ROW China risk persists due to Unreliable Entities List.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Illumina lifts 2026 guidance on strong Q2; NovaSeq X demand supports upside

Illumina Gets Medicare Boost for Cancer Test, Shares Climb

Illumina unveils dataset to speed up AI-powered drug discovery

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

ILMN Stock vs. IQV Stock